Biogen
1978
FOUNDED
PUBLIC
STATUS
5K-10K
EMPLOYEES
BIIB
STOCK SYMBOL
57
INVESTMENTS
$278.14
SHARE PRICE
(As of Friday Closing)
Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.
Website
Formerly Known As
Biogen Idec
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Primary Office
- 225 Binney Street
- Cambridge, MA 02142
- United States
+1 (781) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Biogen’s full profile, request a free trial.
Biogen Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $215.78 - $338.87 | $50.2B | $284.21 | $28.12 | 1.72M | 180M |
Biogen Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 46,358,201 | 62,126,042 | 70,361,808 | 63,915,571 |
| Revenue | 14,232,900 | 13,452,900 | 12,273,900 | 11,448,800 |
| EBITDA | 7,778,200 | 7,004,300 | 6,382,100 | 5,812,300 |
| Net Income | 5,395,600 | 4,430,700 | 2,539,100 | 3,702,800 |
| Total Assets | 27,484,000 | 25,288,900 | 23,652,600 | 22,876,800 |
| Total Debt | 6,364,000 | 5,936,500 | 5,938,200 | 6,517,400 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Biogen Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Biogen‘s full profile, request access.
Request full access to PitchBookBiogen Competitors (64)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regulus Therapeutics | Corporation | San Diego, CA | 00 | 00000 | 000000 - 000 | 00000 |
| 000000000(00000000 | Formerly VC-backed | New York, NY | 000 | 00000 | 000000 - 000 | 00000 |
| 000000 | Corporation | Seattle, WA | 000 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Corporation | PA | 000 | 000.00 | 00000000 | 000.00 |
| 0000000 | Formerly VC-backed | Summit, NJ | 0000 | 000.00 | 000000&0 | 000.00 |
Biogen Investments & Acquisitions (57)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 (00000000 0 | 13-Jan-2020 | 000000000 00000 00 | 00000 | Buildings and Property | 000000 00000000 00. |
| 0000000000 | 07-Jun-2019 | 000000000000000000 | 00000 | Biotechnology | 000000 000000000 |
| 0000000 0000000 | 31-Dec-2018 | 000000000 00000000 | 00000 | Biotechnology | 0000000 0000000 |
| 00000000 000 | 24-Jul-2018 | 000000000000000000 | 00000 | Biotechnology | |
| Ionis Pharmaceuticals | 11-Jun-2018 | Secondary Transaction - Private | 000 | Drug Discovery | 000000 000000000 |
Biogen Exits (23)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000 00000000000 | 30-Mar-2017 | 00000 00000 00 | 0000 | Completed |
|
| 00000 000000000000 | 06-Jan-2016 | 00000 00000 00 | 000.00 | Completed |
|
| 00000 00 | 03-Nov-2015 | 00000 00000 00 | 000.00 | Completed |
|
| 0000 00000 0000000 | 17-Jun-2014 | 00000 00000 00 | 0000 | Completed |
|
| Ataxion | 17-Mar-2014 | Early Stage VC | 0000 | Completed |
|
Biogen Subsidiaries (5)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| AliveGen USA | Biotechnology | Thousand Oaks, CA | 2014 |
| 0000000 0000000 | Biotechnology | Incheon, South Korea | 0000 |
| 00000000000 000000 | Biotechnology | Cambridge, United Kingdom | 0000 |
| 0000000 | Biotechnology | NC | 0000 |
| 0000000 | Biotechnology | South San Francisco, CA | 0000 |
Biogen Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Biogen‘s full profile, request access.
Request full access to PitchBookBiogen Executive Team (69)
49 Former Executives
You’re viewing 5 of 69 executives. Get the full list »Biogen Board Members (10)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Alexander Denner Ph.D | Self | Director and Chairman, Corporate Governance Committee | 000 0000 | |
| Brian Posner | Self | Director & Chairman, Finance Committee | 000 0000 | |
| Caroline Dorsa | Biogen | Board Member & Chairman, Audit Committee | 000 0000 | |
| Eric Rowinsky MD | Self | Board Member | 000 0000 | |
| Lynn Schenk | Biogen | Board Member and Chairman, Risk Committee | 000 0000 |
1 Former Board Member
You’re viewing 5 of 10 board members. Get the full list »